(NASDAQ: OTLK) Outlook Therapeutics's forecast annual revenue growth rate of 232.9% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Outlook Therapeutics's revenue in 2025 is $1,505,322.On average, 4 Wall Street analysts forecast OTLK's revenue for 2025 to be $284,240,566, with the lowest OTLK revenue forecast at $133,258,587, and the highest OTLK revenue forecast at $558,175,801. On average, 4 Wall Street analysts forecast OTLK's revenue for 2026 to be $1,210,076,809, with the lowest OTLK revenue forecast at $707,158,902, and the highest OTLK revenue forecast at $2,263,175,003.
In 2027, OTLK is forecast to generate $2,599,386,418 in revenue, with the lowest revenue forecast at $857,741,105 and the highest revenue forecast at $4,341,076,150.